Search

Focuses on the compensation of workers and the resultant increase of injuries in the industries. Laws used to exonerate employers in defense to injuries of employees at work places; Legislation of Employer's Liability Statutes; Worker's Compensation as protection for employees.

Background: With term GIST is now defined a group of mesenchimal tumours of the gastrointestinal tract expressing immunopositivity for kit protein kinase (CD117). Surgical therapy remains the gold standard for these rare tumours. Imatinib Mesylate (STI-571) is a potent inhibitor of Kit Kinase activity and different reports demonstrated its efficacy in unresectable or metastatic Gists., Aim of the Paper: To value the incidence of GISTs among gastric mesenchimal neoplasms and analyzed their clinical presentation, prognostic parameters and surgical treatment. The response to Imatinib Mesylate in a case of metastatic GIST is then valued., Methods: Twelve cases of gastric mesenchimal neoplasms are retrospectively reviewed and tested by CD117 immmunopositivity identifyng 8 GISTs. The median follow-up was 37 (range7-120) months. We describe in details the case of a metastatic Gist treated for 15 months with Imatinib Mesylate., Results: The 67 per cent of mesenchimal gastric tumours were CD117+. Gastrointestinal bleeding was the most common presenting symptom. The 50% of patiens with malignant GISTS had a palpable abdominal mass at diagnosis. All tumors < 5 cm in diameter had a mitotic count (MC) <5/50 high-power fields (HPFs) except a case of high grade leiomyosarcoma. Surgical therapy was complete tumour resection with free margins. No recurrence was observed in lesions <5cm and < 5 mitosis/50 High Power Fields (HPFs). A good response to Imatinib Mesylate was reported in a metastatic GIST., Conclusion: The surgeon's role in gastric Gist's treatment is to achieve a complete cancer resection with free margins. In advanced lesions, even in presence of hepatic metastases, surgical resection of the mass is indicated because is possible to obtain a stabilization or a partial remission with Imatinib Mesylate palliative treatment in some patients.

Background: Incisional hernia (IH) repair with conventional techniques is associated with high recurrence rate. Surgical repair using prosthetic biomaterials is becoming increasingly popular. On the basis of the good results an increasing number of surgeons have begun to use this technique. However prosthesis use in contaminated fields is still debated. In complicated IH contaminating surgical procedure are often performed and the use of meshes can be hazardous. The aim of this study was to report our experience about the treatment of complicated IH with prosthetic materials in an emergency surgery setting., Methods: From November 1995 to November 2001 55 patients were submitted to emergency surgical treatment for complicated IH. Eleven patients were treated using a prosthetic device. Patients mean age was 71.3 (range 38-91). About 70% of patients had concomitant major cardiac or pulmonary diseases., Results: Thirty-two IH were strangulated, 23 were incarcerated. In all patients a viscerolysis was carried out. In 6 patients a small bowel resection was done and in 4 subjects a large bowel resection was performed. Eight patients were submitted to omental resection. There were not differences in morbidity and mortality between the studied group. Recurrence rate was significantly lower in prosthetic treated group., Conclusions: We concluded that prosthetic repair of complicated IH is feasible in selected cases allowing abdominal wall anatomy re-establishment.

Glucagonoma, a rare neuroendocrine pancreatic tumour, is frequently malignant and often accompanied by hepatic metastases. Our aim was to consider the different treatments of metastatic glucagonoma to the liver and their results. A case of glucagonoma with metachronous, small, multiple and bilobar liver metastases is reported. Combined treatment with octreotide and hepatic arterial chemoembolization was applied with good results in terms of symptom relief, plasma glucagon levels and regression of hepatic metastases. Survival rates were also improved. Based on our experience, glucagonoma with metachronous, multiple, diffuse and bilobar hepatic metastases should be treated with octreotide plus hepatic arterial chemoembolization with improved outcome and prognosis.